Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm, safety and efficacy CLASP study.
SAN FRANCISCO -- The Pascal device remained noninferior to MitraClip for prohibitive surgical risk patients with significant symptomatic degenerative mitral regurgitation (DMR) in full results from ...
Edwards Lifesciences Corp. ((EW)) announced an update on their ongoing clinical study. Edwards Lifesciences Corp. is currently conducting a pivotal clinical trial titled ‘Edwards PASCAL Transcatheter ...
LONDON, England—Two-year results from the CLASP IID randomized trial and registry confirm the early benefits of transcatheter edge-to-edge repair (TEER) with the Pascal system (Edwards Lifesciences) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results